The startup operates an immune-modulating therapeutics platform that develops targeted treatments for cancer by enhancing immune responses while preserving healthy tissue. This approach addresses the limitations of existing therapies by providing more effective treatment options with reduced side effects.
Funding
$8.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often harm healthy tissues while targeting cancerous cells, leading to significant side effects and limiting treatment effectiveness. Existing immunotherapies may not be targeted enough, resulting in systemic immune responses and potential autoimmune reactions.
Solution
The startup is developing a targeted immune-modulating therapeutics platform designed to enhance anti-cancer immune responses while minimizing damage to healthy tissue. This approach aims to create more effective cancer treatments with fewer side effects by precisely directing the immune system to attack tumor cells. The platform focuses on developing therapies that selectively activate or suppress specific immune pathways within the tumor microenvironment. By modulating the immune response directly at the site of the tumor, the platform seeks to improve treatment outcomes and reduce the risk of systemic toxicity. The goal is to provide a more precise and personalized approach to cancer immunotherapy.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and cancer patients seeking more effective and less toxic treatment options.
Features
- Targeted immune modulation within the tumor microenvironment
- Development of therapies that selectively activate or suppress specific immune pathways
- Focus on minimizing damage to healthy tissue
- Personalized approach to cancer immunotherapy